{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:14:42Z","timestamp":1793319282651,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40120-023-00464-x","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T10:45:45Z","timestamp":1683801945000},"page":"1573-1590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03052751","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8234-2896","authenticated-orcid":false,"given":"Antoine","family":"Regnault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0690-5359","authenticated-orcid":false,"given":"Thomas","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5896-5927","authenticated-orcid":false,"given":"Christine","family":"de la Loge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3854-632X","authenticated-orcid":false,"given":"Flora","family":"Mazerolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8195-0141","authenticated-orcid":false,"given":"Henry J.","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3432-9747","authenticated-orcid":false,"given":"Ali A.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"issue":"6","key":"464_CR1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.23330","volume":"45","author":"M Benatar","year":"2012","unstructured":"Benatar M, Sanders DB, Burns TM, Cutter GR, Guptill JT, Baggi F, et al. Recommendations for myasthenia gravis clinical trials. Muscle Nerve. 2012;45(6):909\u201317.","journal-title":"Muscle Nerve"},{"key":"464_CR2","doi-asserted-by":"crossref","unstructured":"Thomsen JLS, Andersen H. Outcome measures in clinical trials of patients with myasthenia gravis. Front Neurol. 2020;11.","DOI":"10.3389\/fneur.2020.596382"},{"issue":"2","key":"464_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","volume":"36","author":"C Barnett","year":"2018","unstructured":"Barnett C, Herbelin L, Dimachkie MM, Barohn RJ. Measuring clinical treatment response in myasthenia gravis. Neurol Clin. 2018;36(2):339\u201353.","journal-title":"Neurol Clin"},{"issue":"1","key":"464_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score a. Ann N Y Acad Sci. 1998;841(1):769\u201372.","journal-title":"Ann N Y Acad Sci."},{"issue":"18","key":"464_CR5","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","volume":"74","author":"TM Burns","year":"2010","unstructured":"Burns TM, Conaway M, Sanders DB, Composite MG, Group M-QS. The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology. 2010;74(18):1434\u201340.","journal-title":"Neurology"},{"key":"464_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06817.x","volume":"1274","author":"S Muppidi","year":"2012","unstructured":"Muppidi S. The myasthenia gravis\u2013specific activities of daily living profile. Ann N Y Acad Sci. 2012;1274:114\u20139.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"464_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1749-6632.2012.06812.x","volume":"1274","author":"TM Burns","year":"2012","unstructured":"Burns TM. The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice. Ann N Y Acad Sci. 2012;1274(1):99\u2013106.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"464_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/mus.25529","volume":"56","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Freimer M, O\u2019Brien F, Wang JJ, Collins SR, Kissel JT, et al. QMG and MG-ADL correlations: study of eculizumab treatment of myasthenia gravis. Muscle Nerve. 2017;56(2):328\u201330.","journal-title":"Muscle Nerve"},{"issue":"2","key":"464_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/mus.26910","volume":"62","author":"T McPherson","year":"2020","unstructured":"McPherson T, Aban I, Duda PW, Farzaneh-Far R, Wolfe GI, Kaminski HJ, et al. Correlation of quantitative myasthenia gravis and myasthenia gravis activities of daily living scales in the MGTX study. Muscle Nerve. 2020;62(2):261\u20136.","journal-title":"Muscle Nerve"},{"issue":"5","key":"464_CR10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","volume":"44","author":"S Muppidi","year":"2011","unstructured":"Muppidi S, Wolfe GI, Conaway M, Burns TM, Mg C, Mg-Qol15 Study G. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44(5):727\u201331.","journal-title":"Muscle Nerve"},{"issue":"8","key":"464_CR11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2014eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377.","journal-title":"Value Health"},{"issue":"8","key":"464_CR12","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2014assessing respondent understanding. Value Health. 2011;14(8):978\u201388.","journal-title":"Value Health"},{"issue":"1","key":"464_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-021-02064-0","volume":"16","author":"S Cleanthous","year":"2021","unstructured":"Cleanthous S, Mork A-C, Regnault A, Cano S, Kaminski HJ, Morel T. Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease. Orphanet J Rare Dis. 2021;16(1):1\u201314.","journal-title":"Orphanet J Rare Dis"},{"key":"464_CR14","doi-asserted-by":"crossref","unstructured":"Snyder C, Crossnohere N, King M, Reeve BB, Bottomley A, Calvert M, et al. The PROTEUS-trials consortium: optimizing the use of patient-reported outcomes in clinical trials. Clin Trials. 2022:17407745221077691.","DOI":"10.1177\/17407745221077691"},{"issue":"5","key":"464_CR15","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jama.2022.11238","volume":"328","author":"KP Weinfurt","year":"2022","unstructured":"Weinfurt KP, Reeve BB. Patient-reported outcome measures in clinical research. JAMA. 2022;328(5):472\u20133.","journal-title":"JAMA"},{"key":"464_CR16","doi-asserted-by":"crossref","unstructured":"Brundage MD, Crossnohere NL, O\u2019Donnell J, Cruz Rivera S, Wilson R, Wu AW, et al. Listening to the patient voice adds value to cancer clinical trials. JNCI: Journal of the National Cancer Institute. 2022.","DOI":"10.1093\/jnci\/djac128"},{"key":"464_CR17","doi-asserted-by":"crossref","unstructured":"Litchfield I, Greenfield S, Turner GM, Finnikin S, Calvert MJ. Implementing PROMs in routine clinical care: a qualitative exploration of GP perspectives. BJGP Open. 2021;5(1).","DOI":"10.3399\/bjgpopen20X101135"},{"key":"464_CR18","doi-asserted-by":"crossref","unstructured":"Campbell R, Ju A, King MT, Rutherford C. Perceived benefits and limitations of using patient-reported outcome measures in clinical practice with individual patients: a systematic review of qualitative studies. Qual Life Res. 2021:1\u201324.","DOI":"10.1007\/s11136-021-03003-z"},{"issue":"1","key":"464_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-017-0718-x","volume":"12","author":"T Morel","year":"2017","unstructured":"Morel T, Cano SJ. Measuring what matters to rare disease patients\u2013reflections on the work by the IRDiRC taskforce on patient-centered outcome measures. Orphanet J Rare Dis. 2017;12(1):1\u201313.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"464_CR20","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1007\/s00415-018-8995-4","volume":"265","author":"T Alekseeva","year":"2018","unstructured":"Alekseeva T, Gavrilov Y, Kreis O, Valko P, Weber K, Valko Y. Fatigue in patients with myasthenia gravis. J Neurol. 2018;265(10):2312\u201321.","journal-title":"J Neurol"},{"issue":"6","key":"464_CR21","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","volume":"96","author":"V Bril","year":"2021","unstructured":"Bril V, Benatar M, Andersen H, Vissing J, Brock M, Greve B, et al. Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial. Neurology. 2021;96(6):e853\u201365.","journal-title":"Neurology"},{"issue":"4","key":"464_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/CND.0b013e31824619d5","volume":"13","author":"C Barnett","year":"2012","unstructured":"Barnett C, Katzberg H, Nabavi M, Bril V. The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers. J Clin Neuromuscul Dis. 2012;13(4):201\u20135.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"6","key":"464_CR23","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/mus.21185","volume":"38","author":"TM Burns","year":"2008","unstructured":"Burns TM, Conaway MR, Cutter GR, Sanders DB. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve. 2008;38(6):1553\u201362.","journal-title":"Muscle Nerve"},{"key":"464_CR24","unstructured":"Rasch G. Studies in mathematical psychology: I. Probabilistic models for some intelligence and attainment tests. 1960."},{"key":"464_CR25","doi-asserted-by":"publisher","DOI":"10.4135\/9781412985598","volume-title":"Rasch models for measurement","author":"D Andrich","year":"1988","unstructured":"Andrich D. Rasch models for measurement. Newbury Park: Sage; 1988."},{"key":"464_CR26","doi-asserted-by":"crossref","unstructured":"Hobart J, Cano S. Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. Health Technol Assess. 2009;13(12):iii, ix-x, 1\u2013177.","DOI":"10.3310\/hta13120"},{"key":"464_CR27","unstructured":"Wright BD, Masters GN. Rating scale analysis. Mesa Press; 1982."},{"key":"464_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/BF02293814","volume":"43","author":"D Andrich","year":"1978","unstructured":"Andrich D. A rating formulation for ordered response categories. Psychometrika. 1978;43:561\u201373.","journal-title":"Psychometrika"},{"issue":"3","key":"464_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3233\/JND-150082","volume":"2","author":"C Barnett","year":"2015","unstructured":"Barnett C, Merkies IS, Katzberg H, Bril V. Psychometric properties of the quantitative myasthenia gravis score and the myasthenia gravis composite scale. J Neuromusc Dis. 2015;2(3):301\u201311.","journal-title":"J Neuromusc Dis"},{"issue":"6","key":"464_CR30","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/mus.23260","volume":"45","author":"R Sadjadi","year":"2012","unstructured":"Sadjadi R, Conaway M, Cutter G, Sanders DB, Burns TM, Group MCMQS. Psychometric evaluation of the myasthenia gravis composite using Rasch analysis. Muscle Nerve. 2012;45(6):820\u20135.","journal-title":"Muscle Nerve"},{"issue":"1","key":"464_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1749-6632.2011.06123.x","volume":"1233","author":"A Serra","year":"2011","unstructured":"Serra A, Ruff R, Kaminski H, Leigh RJ. Factors contributing to failure of neuromuscular transmission in myasthenia gravis and the special case of the extraocular muscles. Ann N Y Acad Sci. 2011;1233(1):26\u201333.","journal-title":"Ann N Y Acad Sci"},{"key":"464_CR32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1196\/annals.1405.037","volume":"1132","author":"J Soltys","year":"2008","unstructured":"Soltys J, Gong B, Kaminski HJ, Zhou Y, Kusner LL. Extraocular muscle susceptibility to myasthenia gravis unique immunological environment? Ann N Y Acad Sci. 2008;1132:220.","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"464_CR33","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.nmd.2021.05.007","volume":"31","author":"LK Andersen","year":"2021","unstructured":"Andersen LK, Aadahl M, Vissing J. Fatigue, physical activity and associated factors in 779 patients with myasthenia gravis. Neuromuscul Disord. 2021;31(8):716\u201325.","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"464_CR34","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.nmd.2020.06.010","volume":"30","author":"AM Ruiter","year":"2020","unstructured":"Ruiter AM, Verschuuren JJ, Tannemaat MR. Fatigue in patients with myasthenia gravis. A systematic review of the literature. Neuromusc Disord. 2020;30(8):631\u20139.","journal-title":"Neuromusc Disord."},{"issue":"9","key":"464_CR35","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1212\/WNL.0000000000002971","volume":"87","author":"C Barnett","year":"2016","unstructured":"Barnett C, Bril V, Kapral M, Kulkarni A, Davis AM. Development and validation of the myasthenia gravis impairment index. Neurology. 2016;87(9):879\u201386.","journal-title":"Neurology"}],"updated-by":[{"DOI":"10.1007\/s40120-023-00508-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000}}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00464-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00464-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00464-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T18:07:32Z","timestamp":1702404452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00464-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["464"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00464-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40120-023-00508-2","asserted-by":"object"}]},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"1 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40120-023-00508-2","URL":"https:\/\/doi.org\/10.1007\/s40120-023-00508-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}